相关实验视频

Updated: Jun 19, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 10, 2014

评估儿童多发性硬化症患者的疗效结果,同时通过USNPMSC注册表通过使用Avonex或Plegridy

Melissa A Wright¹, Bradley J Barney¹, Skyler Peterson¹

¹Department of Pediatrics (MAW, BJB, SP, MW, TCC), Utah Data Coordinating Center (BJB), and Department of Neurology (JR), University of Utah, Salt Lake City, UT, USA.

Journal of child neurology

|September 16, 2025

概括

肌内干扰素β-1a (Avonex) 和皮下干扰素β-1a (Plegridy) 在预防儿科多发性硬化症患者复发方面表现出类似的有效性. 这些疾病修饰疗法可能会使年轻患者受益,尽管缺乏正式批准.

科学领域:

神经学神经学
免疫学免疫学免疫学
儿科儿科儿科

背景情况:

多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
疾病修饰疗法 (DMT) 对于治疗多发性硬化症至关重要,但对儿科患者的数据有限.
肌肉内干扰素β-1a (Avonex) 和皮下干扰素β-1a (Plegridy) 是已知的多发性硬化症治疗方法.

研究的目的:

为了评估Avonex和Plegridy在患有多发性硬化症的儿科患者中的疗效.
为了在这个队列中比较Avonex和Plegridy之间的复发率和无复发概率.
评估这些DMT在患有MS的青少年中的潜在益处.

主要方法:

来自美国儿科多发性硬化中心网络的154名儿科多发性硬化患者的回顾性分析.
纳入标准:在18岁之前接受阿文克斯,Plegridy或两者的治疗.
数据收集包括3个月的"洗"期后的复发状态.

主要成果:

在第一年没有复发的概率:阿维尼克斯68.3%,Plegridy69.9%.
年化复发率:阿文尼克斯为0.50,Plegridy为0.59.
儿科患者的疗效与成年人群中观察到的疗效相当.

结论:

艾沃内克斯和Plegridy在儿童多发性硬化症患者中表现出可比的疗效.
这些DMT可以为患有多发性硬化症的青少年提供好处,即使没有正式的儿科批准.
儿童多发性硬化症的知情治疗决策需要了解DMT在这个年龄组的疗效.

关键词:

艾文尼克斯公司 (Avonex)这是一种谤.疾病修饰疗法 (DMT) 是一种疾病修饰疗法.干扰子干扰子干扰子儿科多发性硬化症儿童多发性硬化症

更多相关视频

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Intrathecal Vector Delivery in Juvenile Rats via Lumbar Cistern Injection

Intrathecal Vector Delivery in Juvenile Rats via Lumbar Cistern Injection

Published on: March 29, 2024

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...